Detalhe da pesquisa
1.
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
Blood
; 139(7): 1066-1079, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699595
2.
Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia.
Wien Med Wochenschr
; 173(1-2): 27-33, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36414855
3.
Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.
Wien Med Wochenschr
; 173(1-2): 34-40, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282401
4.
Significance of reduced renal function in patients with chronic myelomonocytic leukemia.
Wien Med Wochenschr
; 173(1-2): 3-8, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282402
5.
Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia.
Wien Med Wochenschr
; 173(1-2): 9-14, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36205826
6.
Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia.
Wien Med Wochenschr
; 173(1-2): 21-26, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36445600
7.
Significance of C-reactive protein in patients with chronic myelomonocytic leukemia.
Wien Med Wochenschr
; 173(1-2): 15-20, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36441359
8.
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
BMC Cancer
; 22(1): 1013, 2022 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36153475
9.
Multistep pathogenesis of chronic myelomonocytic leukemia in patients.
Eur J Haematol
; 109(1): 50-57, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35299281
10.
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(5): 678-689, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33848462
11.
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Ann Rheum Dis
; 80(1): 71-87, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33158881
12.
Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study.
BMC Cancer
; 21(1): 754, 2021 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34187419
13.
Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival.
Eur J Haematol
; 106(5): 627-633, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33432601
14.
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
Eur J Haematol
; 107(2): 265-274, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33998054
15.
S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis.
Respiration
; 100(3): 238-271, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33486500
16.
Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.
Haematologica
; 105(2): 375-386, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097632
17.
A Comparison of Existing Questionnaires for Identifying the Causes of Interstitial and Rare Lung Diseases.
Respiration
; 99(2): 119-124, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32000164
18.
Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.
Int J Mol Sci
; 21(17)2020 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32842710
19.
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
Int J Mol Sci
; 21(8)2020 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32344757
20.
Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial.
Invest New Drugs
; 37(1): 127-138, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29998365